A Randomized, Open-label, Parallel Design Study of the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products After Administration of Single Subcutaneous Doses

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Aug 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dupilumab (Primary)
Indications Aspergillosis; Asthma; Atopic dermatitis; Bullous pemphigoid; Chronic obstructive pulmonary disease; Chronic urticaria; Eczema; Eosinophilic gastroenteritis; Eosinophilic oesophagitis; Milk hypersensitivity; Prostate cancer; Prurigo nodularis; Pruritus; Rhinosinusitis; Ulcerative colitis; Urticaria
Focus Pharmacokinetics
Sponsors Sanofi

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com